Aurinia Pharmaceuticals Inc. announced that for fiscal year 2022, the Company is providing net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150% to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.21 USD | -0.57% | -9.55% | -42.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.05% | 743M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022